PURE — PURE Biosciences Income Statement
0.000.00%
Last trade - 00:00- $7.49m
- $8.80m
- $1.88m
- 35
- 15
- 17
- 11
Annual income statement for PURE Biosciences, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.91 | 6.92 | 3.93 | 1.85 | 1.88 |
| Cost of Revenue | |||||
| Gross Profit | 1.18 | 4.02 | 2.08 | 1 | 0.971 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.5 | 6.91 | 6.24 | 5.34 | 5.82 |
| Operating Profit | -5.59 | 0.004 | -2.31 | -3.48 | -3.94 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.55 | 0.004 | -2.32 | -3.49 | -3.96 |
| Net Income After Taxes | -6.55 | 0.004 | -2.32 | -3.49 | -3.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.55 | 0.004 | -2.32 | -3.49 | -3.96 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.55 | 0.004 | -2.32 | -3.49 | -3.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.09 | 0 | -0.027 | -0.039 | -0.033 |